Trimelvax001TRIMELVax Vaccine for Stage IIIC and IV Melanoma Patients

Cancer vaccines offer a new hope for patients with advanced melanoma who have not responded well to other treatments like immune checkpoint blockers. TRIMELVax is an innovative vaccine being tested for its safety in people with late-stage melanoma. This vaccine is created from specially treated melanoma cells combined with a natural booster to help the body recognize and fight the cancer. The study focuses on adults over 18 with stage IIIC or IV melanoma who have either not benefited from or experienced serious side effects from existing treatments. By exploring this vaccine, the study aims to improve treatment options and potentially offer a new pathway for those battling advanced melanoma. In this study, participants will receive TRIMELVax through a series of four shots given under the skin. Researchers will closely monitor for any side effects using established criteria to ensure that the treatment is safe. To understand how the vaccine works, blood samples will be collected from participants before and after treatment to check how the immune system is responding. Additionally, a test will be performed a month after the last injection to further assess the body's immune response. Through these methods, the study aims to gather detailed information about the vaccine's impact on the immune system and its overall safety for patients.